GSK and the University of California have collaborated for five years to establish an advanced laboratory for genomic research, the Laboratory for Genomic Research (LGR).
The main motto of the collaboration is to study how genetic mutations result in disease, thereby advancing the drug research.
The idea was from Prof. Jennifer Doudna (UCB), Prof. Jonathan Weissman (UCSF) and Dr. Hal Barron (GSK).
CRISPR-Cas9 is a technology intended to slice accurately at a part of DNA. The sliced DNA can be replaced by the researcher.
It is expected that this technology enables to develop new therapies for diseases.
LGR enables the researcher and industry professionals to come under one roo. Outcomes are targeted at developing new technologies, drug targets and biological mechanisms.